Summary & Overview
CPT 0623U: TruD MDS Multiple Sclerosis DNA Methylation Test
CPT code 0623U represents a Proprietary Laboratory Analyses (PLA) molecular diagnostic test: the TruD MDS Multiple Sclerosis assay from TruDiagnostic™ Inc. The test evaluates DNA methylation at over 5,000 sites from a whole blood sample and classifies results as a positive or negative risk for multiple sclerosis. As a PLA code, 0623U is specific to a single manufacturer’s assay and is used nationally to identify and bill for this unique laboratory service.
Key payers considered in this publication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for the assay, the service and typical site of service, and what the PLA designation means for coding and payer identification. The guide outlines expected topics covered in the fuller publication: national coverage and reimbursement benchmarks where available, payer coverage considerations, coding and billing implications for laboratories and ordering clinicians, and the clinical utility of DNA methylation profiling in autoimmune (multiple sclerosis) risk reporting.
Data not provided in the input are noted explicitly in the relevant sections of the full publication. The summary is intended for national audiences seeking a clear understanding of what CPT code 0623U denotes and where it fits in laboratory molecular diagnostics for multiple sclerosis.
Billing Code Overview
CPT code 0623U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the TruD MDS Multiple Sclerosis test from TruDiagnostic™ Inc. The assay analyzes DNA methylation at more than 5,000 sites using a whole blood sample and uses an algorithm to report a positive or negative risk result for autoimmune multiple sclerosis.
Service Type: Clinical laboratory molecular diagnostic test using DNA methylation profiling.
Typical Site of Service: Clinical laboratory or point-of-care collection site with whole blood specimen collection (e.g., outpatient phlebotomy, physician office, or independent laboratory collection site).
Clinical & Coding Specifications
Clinical Context
A 38-year-old patient with a 6-month history of intermittent numbness, gait imbalance, and visual disturbances presents to a neurology clinic for evaluation of possible multiple sclerosis (MS). Prior workup includes neurologic examination, MRI of the brain and spinal cord showing nonspecific white matter lesions, and lumbar puncture with equivocal oligoclonal band results. The neurologist orders the proprietary methylation-based blood test 0623U (TruD MDS Multiple Sclerosis, TruDiagnostic™ Inc.) to aid in assessment of autoimmune risk by analyzing DNA methylation at >5,000 CpG sites in whole blood and reporting a positive or negative risk result.
Clinical workflow:
-
The clinician documents clinical indication and obtains informed consent for the proprietary laboratory analysis.
-
A whole blood sample is collected in the facility’s phlebotomy area or outpatient lab and prepared per the manufacturer’s collection and shipping instructions.
-
The specimen is shipped to TruDiagnostic™ Inc. for processing. The laboratory performs DNA extraction, methylation profiling, and applies the proprietary algorithm to generate a positive/negative risk report for MS-related autoimmune signal.
-
The laboratory report is returned to the ordering clinician and integrated into the patient’s chart.
-
The ordering clinician interprets the result in context with MRI, cerebrospinal fluid studies, and clinical criteria to inform diagnostic impressions and ongoing management planning.
Typical site of service: outpatient neurology clinic, outpatient phlebotomy laboratory, or independent clinical laboratory performing the PLA service.